Clearbridge Health's second batch of the Sinopharm Covid-19 vaccine has arrived in Singapore, according to a filing to the Singapore Exchange (SGX) on Sept 22.
The group’s first shipment of the Sinopharm vaccine arrived on August 28 and was fully allocated by early September.
Clearbridge Health acquired the vaccines from manufacturers in China, including China National Biotec Group Company Limited (CNBG) and Beijing Institute of Biological Product Co, a subsidiary of CNBG.
See also: Clearbridge Health receives first shipment of Sinopharm Covid-19 Vaccine
The company also facilitated other healthcare institutions in Singapore to get access to the Sinopharm vaccine.
Part of this second vaccine shipment will be allocated to the Royal Healthcare Specialists Centre, under the Special Access Route approval from the Health Sciences Authority of Singapore.
The Sinopharm vaccine has been authorised for conditional and emergency use in several countries including the People’s Republic of China, the United Arab Emirates, Malaysia, Thailand and Indonesia. It has also been listed by the World Health Organization for emergency use.
Medic Surgical & Laser Clinic, operated by a Clearbridge Health subsidiary, has been granted approval to import and supply the Sinopharm Covid-19 Vaccine in Singapore for six months from July 6.
As at 9.07am, shares in Clearbridge Health are trading up 0.5 cents or 3.79% higher at 13.7 cents.
